Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Schering-Plough |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00038584 |
SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death.
This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Squamous Cell Cancer of Head and Neck |
Drug: SCH66336 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Safety Study |
Official Title: | A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Laboratory values (performed within 14 days prior to administration of SCH 66336):
Exclusion Criteria:
Responsible Party: | U.T. M.D. Anderson Cancer Center ( Merrill Kies, MD / Professor ) |
Study ID Numbers: | ID98-251 |
Study First Received: | May 31, 2002 |
Last Updated: | August 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00038584 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Head and Neck Neoplasms Epidermoid Carcinoma Neoplasms, Squamous Cell Squamous Cell Carcinoma |
Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Head and Neck Neoplasms |
Neoplasms, Squamous Cell Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial Carcinoma |